In Combination

1. Developing Therapy Delivery Options For Autoimmune And Allergic Diseases At Revolo Biotherapeutics 4/22/2025

   In this episode of In Combination, host Tom von Gunden combines the perspectives of three executives at Revolo Biotherapeutics – CEO Woody Bryan, Chief Scientific Officer Roly Foulkes, and Chief Medical Officer Kari Brown – in a discussion about developing and delivering peptide-based alternatives to steroids for allergic and autoimmune diseases.

2. Formulations, Devices, Regulations, and Patients: Two Takes On Drug Delivery Trends 3/14/2025

   In this unique episode of In Combination, series host Tom von Gunden, Chief Editor at Drug Delivery Leader, puts himself in combination with DDL Executive Editor Fran DeGrazio as the two share perspectives on drug delivery trends.

3. Developing A Combination Product: Early-Stage Formulation And Device Considerations At GSK 2/5/2025

   Successful development of a safe and effective combination product depends on careful consideration of factors impacting the alignment between drug formulation and delivery device. In this episode of In Combination, host Tom von Gunden combines the perspectives of three functional area leads who work collaboratively during early-stage product development and device selection at GSK.

4. Needle-Free Rescue Therapies With Crossject's Patrick Alexandre And Dan Chiche 11/12/2024

   Just how quickly might the emergency treatment of an epileptic seizure or other sudden, chronic attack be enabled? With advances in needle-free autoinjectors, the promise of near immediacy is near. In this episode of In Combination, host Tom von Gunden combines perspectives from two different executive roles at emergency medicines company Crossject. CEO Patrick Alexandre and Chief Medical Officer Dan Chiche discuss common rescue scenarios, rapid self-administration of treatments, and collaborative development efforts across drug formulation and device engineering.

5. LNP-Delivered mRNA via Inhalation with Ethris' Carsten Rudolph and Thomas Langenickel 9/18/2024

   How can genetic information be carried into lung tissue for the treatment of asthma and potentially other conditions? In this inaugural episode of In Combination, host Tom von Gunden combines the perspectives of two executives from LNP/mRNA (lipidoid nanoparticle / messenger RNA) formulation and delivery platform developer Ethris: CEO Carsten Rudolph and Chief Medical Officer Thomas Langenickel. The conversation illuminates the value to patients of platform approaches to inhalation-delivered treatments.